Ashley Stracco ‘28
Staff Writer
Recently, there has been a dispute over federal health research money after Budget Chief Russ Vought drafted an executive order to create a political board that decides which grants the National Institutes of Health (NIH) can fund. This action has prompted debate as the country heads into the November 2026 midterms. Debates on this issue have centered around whether or not this move is a necessary measure to ensure government accountability or if it is just an unconstitutional overreach that could exert partisan control over scientific research.
Earlier this week, tensions between the White House and the scientific community have escalated when NIH Director Jay Bhattacharya resisted administrative requests to strip Harvard University of its federal research funding. Meanwhile, the Trump administration is attempting to implement a unanimous-consent veto board through executive action rather than seeking congressional legislation or an appropriations vote. For some, this raises the question about the boundaries between executive authority and congressional control over federal funds. This issue has put healthcare policy directly in the spotlight of the political debate as the country heads toward the 2026 midterm elections.
One core issue in this case is the boundaries between executive authority and legislative control over issues regarding public health. Congress holds the “power of the purse,’ and since the executive branch is directing the distribution of billions of dollars in medical research funds, a precedent for future issues and administrations is created. Critics of the decision argue that the allowance of a presidential administration to filter scientific grants through political appointees turns the federal healthcare administration, at least in part, into a partisan tool, especially with the Nov. 2026 midterm elections among us.
The debate points toward the current dispute on Capitol Hill. Currently, Congress relies on a stopgap spending bill passed earlier this month to temporarily block an earlier version of the White House’s grant-control plan, all while vital federal funding remains unstable as deadlines loom in Dec. 2026. It can be argued that rather than working toward long-term structural protections for public science, lawmakers are using the looming deadlines regarding healthcare to win their upcoming midterm elections.
As a result, The White House and Congress have responded to these issues in completely different ways. On one hand, the Trump administration has responded by fast-tracking executive directives to install a board capable of vetoing specific topics of research. Republican Senate Appropriations Chair Susan Collins and key congressional leaders have responded by blocking the administration’s overreach to protect traditional legislative authority.
Image courtesy of the sun
Leave a Reply